Literature DB >> 19427424

Safety and benefit of early elective percutaneous coronary intervention after successful thrombolytic therapy for acute myocardial infarction.

Doo Sun Sim1, Myung Ho Jeong, Youngkeun Ahn, Young Jo Kim, Shung Chull Chae, Taek Jong Hong, In Whan Seong, Jei Keon Chae, Chong Jin Kim, Myeong Chan Cho, Ki Bae Seung, Seung Jung Park.   

Abstract

The aim of this study was to assess the safety and benefits of early elective percutaneous coronary intervention (PCI) after successful thrombolytic therapy for acute myocardial infarction. Early elective PCI after successful thrombolysis is controversial, and the optimal time for PCI is elusive. Using data from the Korea Acute Myocardial Infarction Registry from November 2005 to June 2007, a total of 383 patients with acute myocardial infarction who underwent elective PCI within 2 weeks of successful thrombolytic therapy were grouped based on time between thrombolysis and PCI as group 1, <24 hours (n = 81, age 59.5 +/- 10.5 years, 10.9 +/- 7.2 hours); group 2, > or =24 and <48 hours (n = 79, 59.5 +/- 11.6 years, 36.4 +/- 6.8 hours); group 3, > or =48 hours and <72 hours (n = 79, 61.0 +/- 10.9 years, 59.8 +/- 6.8 hours); and group 4, >72 hours (n = 144, 61.7 +/- 12.9 years, 117.8 +/- 48.5 hours). Primary study outcomes included major bleeding, in-hospital death, and major adverse cardiac events (MACEs; cardiac death, myocardial infarction, repeated PCI, and coronary artery bypass surgery) at 1, 6, and 12 months. There were no differences among the 4 groups in baseline clinical characteristics and angiographic findings. There were no differences in the incidences of major bleeding, in-hospital mortality, and 1-month outcomes among groups. Rates of composite MACEs and repeated PCI at 6 and 12 months were significantly lower in patients who underwent PCI within 48 hours of thrombolytic therapy compared with those who underwent PCI later (6-month MACEs: 1.0% vs 9.5%, p = 0.014; 6-month repeated PCI: 0% vs 6.8%, p = 0.028; 12-month MACEs: 4.1% vs 14.9%, p = 0.026; 12-month repeated PCI: 1.4% vs 9.6%, p = 0.034). In conclusion, early elective PCI within 48 hours of successful thrombolytic therapy for AMI appeared safe and more beneficial compared with PCI performed later.

Entities:  

Mesh:

Year:  2009        PMID: 19427424     DOI: 10.1016/j.amjcard.2009.01.339

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Impact of the metabolic syndrome on the clinical outcome of patients with acute ST-elevation myocardial infarction.

Authors:  Min Goo Lee; Myung Ho Jeong; Youngkeun Ahn; Shung Chull Chae; Seung Ho Hur; Taek Jong Hong; Young Jo Kim; In Whan Seong; Jei Keon Chae; Jay Young Rhew; In Ho Chae; Myeong Chan Cho; Jang Ho Bae; Seung Woon Rha; Chong Jin Kim; Donghoon Choi; Yang Soo Jang; Junghan Yoon; Wook Sung Chung; Jeong Gwan Cho; Ki Bae Seung; Seung Jung Park
Journal:  J Korean Med Sci       Date:  2010-09-17       Impact factor: 2.153

Review 2.  The scientific achievements of the decades in Korean Acute Myocardial Infarction Registry.

Authors:  Hyun Kuk Kim; Myung Ho Jeong; Seung Hun Lee; Doo Sun Sim; Young Joon Hong; Youngkeun Ahn; Chong Jin Kim; Myeong Chan Cho; Young Jo Kim
Journal:  Korean J Intern Med       Date:  2014-10-31       Impact factor: 2.884

Review 3.  Differences in the Korea Acute Myocardial Infarction Registry Compared with Western Registries.

Authors:  Doo Sun Sim; Myung Ho Jeong
Journal:  Korean Circ J       Date:  2017-09-18       Impact factor: 3.243

Review 4.  New horizons of acute myocardial infarction: from the Korea Acute Myocardial Infarction Registry.

Authors:  Ki Hong Lee; Myung Ho Jeong; Youngkeun Ahn; Myeong Chan Cho; Chong Jin Kim; Young Jo Kim
Journal:  J Korean Med Sci       Date:  2013-01-29       Impact factor: 2.153

5.  Differences in Clinical Outcomes Between Patients With ST-Elevation Versus Non-ST-Elevation Acute Myocardial Infarction in Korea.

Authors:  Doo Sun Sim; Ju Han Kim; Myung Ho Jeong
Journal:  Korean Circ J       Date:  2009-08-27       Impact factor: 3.243

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.